Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
ADRB1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| BRETYLIUM | ? unclear | Mechanistic | DGIdb | |
| PINDOLOL | ↑ activates | Mechanistic | DGIdb | |
| BISOPROLOL | ? unclear | Mechanistic | DGIdb | |
| FLECAINIDE ACETATE | ? unclear | Mechanistic | DGIdb | |
| METIPRANOLOL | ? unclear | Mechanistic | DGIdb | |
| METOPROLOL | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| BUCINDOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| METIPRANOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ALPRENOLOL | ? unclear | Mechanistic | 4.88 nM (IC50) | DGIdb |
| PRACTOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| XAMOTEROL | ↑ activates | Mechanistic | DGIdb | |
| PENBUTOLOL | ? unclear | Mechanistic | DGIdb | |
| DOBUTAMINE | ? unclear | Mechanistic | DGIdb | |
| BETHANIDINE | ? unclear | Mechanistic | DGIdb | |
| BETAXOLOL | ? unclear | Mechanistic | 37.1 nM (IC50) | DGIdb |
| MURAGLITAZAR | ? unclear | Mechanistic | DGIdb | |
| ACEBUTOLOL | ? unclear | Mechanistic | DGIdb | |
| LABETALOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ACEBUTOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| NOREPINEPHRINE | ? unclear | Mechanistic | DGIdb | |
| OT-730 | ? unclear | Mechanistic | DGIdb | |
| CARVEDILOL | ↓ inhibits | Mechanistic | DGIdb | |
| NADOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| LEVOBUNOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| LABETALOL | ? unclear | Mechanistic | DGIdb | |
| TERTATOLOL | ? unclear | Mechanistic | DGIdb | |
| ARBUTAMINE | ? unclear | Mechanistic | DGIdb | |
| PROPRANOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ZIPRASIDONE | ? unclear | Mechanistic | DGIdb | |
| BUPRANOLOL | ? unclear | Mechanistic | DGIdb | |
| LANDIOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| OXPRENOLOL | ? unclear | Mechanistic | DGIdb | |
| MEPINDOLOL | ? unclear | Mechanistic | DGIdb | |
| CELIPROLOL | ↓ inhibits | Mechanistic | DGIdb | |
| BISOPROLOL FUMARATE | ↓ inhibits | Mechanistic | DGIdb | |
| DESIPRAMINE | ? unclear | Mechanistic | DGIdb | |
| DOPAMINE | ↑ activates | Mechanistic | DGIdb | |
| ISOPROTERENOL | ↑ activates | Mechanistic | DGIdb | |
| DOBUTAMINE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 288 agents ranked by evidence tier.
AGTR1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CANDESARTAN CILEXETIL | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL586135 | ? unclear | Mechanistic | DGIdb | |
| VALSARTAN | ↓ inhibits | Mechanistic | 4700.0 nM (Ki) | DGIdb |
| EPROSARTAN MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| FIMASARTAN | ↓ inhibits | Mechanistic | DGIdb | |
| ASCORBIC ACID | ? unclear | Mechanistic | DGIdb | |
| OLMESARTAN MEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| AZILSARTAN MEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC ANDROSTANOLONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL347610 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL421088 | ? unclear | Mechanistic | DGIdb | |
| LOSARTAN POTASSIUM | ↓ inhibits | Mechanistic | 5.5 nM (IC50) | DGIdb |
| CHEMBL:CHEMBL1492017 | ? unclear | Mechanistic | DGIdb | |
| SPARSENTAN | ↓ inhibits | Mechanistic | DGIdb | |
| SODIUM CHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL261693 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1972216 | ? unclear | Mechanistic | DGIdb | |
| EPROSARTAN | ? unclear | Mechanistic | 7.3 nM (IC50) | DGIdb |
| C-FOS ANTISENSE | ? unclear | Mechanistic | DGIdb | |
| SARALASIN ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| IRBESARTAN | ↓ inhibits | Mechanistic | 1.1 nM (Ki) | DGIdb |
| DISULFIRAM | ? unclear | Mechanistic | DGIdb | |
| SAPRISARTAN | ? unclear | Mechanistic | DGIdb | |
| H2O2 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL591834 | ? unclear | Mechanistic | DGIdb | |
| CAPTOPRIL | ? unclear | Mechanistic | DGIdb | |
| ANGIOTENSIN II | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL400912 | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| IDOXIFENE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL528694 | ? unclear | Mechanistic | DGIdb | |
| IL-6 | ? unclear | Mechanistic | DGIdb | |
| ANGIOTENSIN II ACETATE | ↑ activates | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| GAMMA-INTERFERON | ? unclear | Mechanistic | DGIdb | |
| AZILSARTAN KAMEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1445650 | ? unclear | Mechanistic | DGIdb | |
| MUSCLE RELAXANT | ? unclear | Mechanistic | DGIdb | |
| CL-329167 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 249 agents ranked by evidence tier.
GJA1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| CARVEDILOL | ? unclear | Mechanistic | DGIdb | |
| PROPYLTHIOURACIL | ? unclear | Mechanistic | DGIdb | |
| BLEOMYCIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| PROTEASOME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| LABETALOL | ? unclear | Mechanistic | DGIdb | |
| PROTEASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| ASCORBIC ACID | ? unclear | Mechanistic | DGIdb | |
| EPIGALLOCATECHIN GALLATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL4793190 | ↓ inhibits | Mechanistic | 4100.0 nM (IC50) | ChEMBL |
| CHEMBL4794431 | ↓ inhibits | Mechanistic | 3100.0 nM (IC50) | ChEMBL |
| CHEMBL4777167 | ↓ inhibits | Mechanistic | 17100.0 nM (IC50) | ChEMBL |
| CHEMBL4777222 | ↓ inhibits | Mechanistic | 26600.0 nM (IC50) | ChEMBL |
| CHEMBL4784426 | ↓ inhibits | Mechanistic | 6200.0 nM (IC50) | ChEMBL |
| CHEMBL4778380 | ↓ inhibits | Mechanistic | 5500.0 nM (IC50) | ChEMBL |
| CHEMBL4790312 | ↓ inhibits | Mechanistic | 6200.0 nM (IC50) | ChEMBL |
| CHEMBL4776897 | ↓ inhibits | Mechanistic | 8900.0 nM (IC50) | ChEMBL |
| CHEMBL4780949 | ↓ inhibits | Mechanistic | 17700.0 nM (IC50) | ChEMBL |
| CHEMBL4785499 | ↓ inhibits | Mechanistic | 8900.0 nM (IC50) | ChEMBL |
| CHEMBL4799209 | ↓ inhibits | Mechanistic | 8600.0 nM (IC50) | ChEMBL |
| KANAMYCIN | ↓ inhibits | Mechanistic | 48000.0 nM (IC50) | ChEMBL |
KCNA5
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DALFAMPRIDINE | ↓ inhibits | Mechanistic | DGIdb | |
| T-226296 | ? unclear | Mechanistic | DGIdb | |
| TEDISAMIL | ↓ inhibits | Mechanistic | DGIdb | |
| AMIFAMPRIDINE PHOSPHATE | ↓ inhibits | Mechanistic | DGIdb | |
| DRONEDARONE | ? unclear | Mechanistic | DGIdb | |
| GUANIDINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| LORATADINE | ? unclear | Mechanistic | DGIdb | |
| BMS-394136 | ? unclear | Mechanistic | DGIdb | |
| VERNAKALANT HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC HORMONE | ? unclear | Mechanistic | DGIdb | |
| BMS-919373 | ? unclear | Mechanistic | DGIdb | |
| DIHYDROTESTOSTERONE | ? unclear | Mechanistic | DGIdb | |
| AMIFAMPRIDINE | ↓ inhibits | Mechanistic | DGIdb | |
| NERISPIRDINE | ↓ inhibits | Mechanistic | DGIdb | |
| TERFENADINE | ? unclear | Mechanistic | DGIdb | |
| VERNAKALANT | ? unclear | Mechanistic | Open Targets | |
| CHEMBL314328 | ↓ inhibits | Mechanistic | 6700.0 nM (IC50) | ChEMBL |
| SERTINDOLE | ↓ inhibits | Mechanistic | 2000.0 nM (IC50) | ChEMBL |
| CHEMBL97793 | ↓ inhibits | Mechanistic | 10000.0 nM (IC50) | ChEMBL |
| CHEMBL97646 | ↓ inhibits | Mechanistic | 3200.0 nM (IC50) | ChEMBL |
| CHEMBL316891 | ↓ inhibits | Mechanistic | 6900.0 nM (IC50) | ChEMBL |
| CHEMBL327334 | ↓ inhibits | Mechanistic | 3800.0 nM (IC50) | ChEMBL |
| CHEMBL288131 | ↓ inhibits | Mechanistic | 100.0 nM (IC50) | ChEMBL |
| CHEMBL433220 | ↓ inhibits | Mechanistic | 9000.0 nM (IC50) | ChEMBL |
| CHEMBL328905 | ↓ inhibits | Mechanistic | 5000.0 nM (IC50) | ChEMBL |
| CHEMBL318879 | ↓ inhibits | Mechanistic | 500.0 nM (IC50) | ChEMBL |
| CHEMBL95368 | ↓ inhibits | Mechanistic | 700.0 nM (IC50) | ChEMBL |
| CHEMBL94826 | ↓ inhibits | Mechanistic | 3500.0 nM (IC50) | ChEMBL |
| CHEMBL418972 | ↓ inhibits | Mechanistic | 6500.0 nM (IC50) | ChEMBL |
| CHEMBL97682 | ↓ inhibits | Mechanistic | 5600.0 nM (IC50) | ChEMBL |
| CHEMBL97828 | ↓ inhibits | Mechanistic | 3100.0 nM (IC50) | ChEMBL |
| CHEMBL319775 | ↓ inhibits | Mechanistic | 1600.0 nM (IC50) | ChEMBL |
| CHEMBL316494 | ↓ inhibits | Mechanistic | 2200.0 nM (IC50) | ChEMBL |
| CHEMBL98077 | ↓ inhibits | Mechanistic | 8500.0 nM (IC50) | ChEMBL |
| CHEMBL327816 | ↓ inhibits | Mechanistic | 600.0 nM (IC50) | ChEMBL |
| CHEMBL319310 | ↓ inhibits | Mechanistic | 500.0 nM (IC50) | ChEMBL |
| CHEMBL273418 | ↓ inhibits | Mechanistic | 600.0 nM (IC50) | ChEMBL |
| CHEMBL420266 | ↓ inhibits | Mechanistic | 6200.0 nM (IC50) | ChEMBL |
| CHEMBL289939 | ↓ inhibits | Mechanistic | 200.0 nM (IC50) | ChEMBL |
| CHEMBL94764 | ↓ inhibits | Mechanistic | 4100.0 nM (IC50) | ChEMBL |
Showing top 40 of 208 agents ranked by evidence tier.
KCNH2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CLARITHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| PYRILAMINE MALEATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL525106 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL584829 | ? unclear | Mechanistic | DGIdb | |
| TAMOXIFEN CITRATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL529640 | ? unclear | Mechanistic | DGIdb | |
| SPIPERONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| NERISPIRDINE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1437888 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602312 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL49055 | ? unclear | Mechanistic | DGIdb | |
| NISOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL591887 | ? unclear | Mechanistic | DGIdb | |
| SOTALOL | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL601492 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1256726 | ? unclear | Mechanistic | DGIdb | |
| N-AMINOHEXYL-5-CHLORO-1-NAPTHALENESULFONAMIDE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| KEPONE | ? unclear | Mechanistic | DGIdb | |
| PHENOXYBENZAMINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL592344 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL582486 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL589946 | ? unclear | Mechanistic | DGIdb | |
| PERPHENAZINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL601528 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL545880 | ? unclear | Mechanistic | DGIdb | |
| GR 89696 | ? unclear | Mechanistic | DGIdb | |
| PD-169316 | ? unclear | Mechanistic | DGIdb | |
| IOFETAMINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL601325 | ? unclear | Mechanistic | DGIdb | |
| BISOPROLOL | ? unclear | Mechanistic | DGIdb | |
| ROPINIROLE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| DROPERIDOL | ? unclear | Mechanistic | 32.2 nM (IC50) | DGIdb |
| CHEMBL:CHEMBL534084 | ? unclear | Mechanistic | DGIdb | |
| OLEIC ACID | ? unclear | Mechanistic | DGIdb | |
| L-741,626 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602580 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580516 | ? unclear | Mechanistic | DGIdb | |
| VINPOCETINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL547488 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 508 agents ranked by evidence tier.
KCNQ1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| EXENATIDE | ? unclear | Mechanistic | DGIdb | |
| NIFLUMIC ACID | ↑ activates | Mechanistic | DGIdb | |
| EZOGABINE | ↑ activates | Mechanistic | DGIdb | |
| DOLASETRON | ? unclear | Mechanistic | DGIdb | |
| GUANIDINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| IKS124 | ↓ inhibits | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| NERISPIRDINE | ↓ inhibits | Mechanistic | DGIdb | |
| PYRITHIONE ZINC | ↑ activates | Mechanistic | DGIdb | |
| SITAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| FLUOROURACIL | ? unclear | Mechanistic | DGIdb | |
| INDAPAMIDE | ? unclear | Mechanistic | DGIdb | |
| MEFENAMIC ACID | ↑ activates | Mechanistic | DGIdb | |
| TEDISAMIL | ↓ inhibits | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| XE991 | ↓ inhibits | Mechanistic | DGIdb | |
| ANHYDROUS TACROLIMUS | ? unclear | Mechanistic | DGIdb | |
| BEPRIDIL | ? unclear | Mechanistic | DGIdb | |
| HMR-1556 | ↓ inhibits | Mechanistic | DGIdb | |
| AMIFAMPRIDINE PHOSPHATE | ↓ inhibits | Mechanistic | DGIdb | |
| (3R,4S)-293B | ↓ inhibits | Mechanistic | DGIdb | |
| L735821 | ↓ inhibits | Mechanistic | DGIdb | |
| DALFAMPRIDINE | ↓ inhibits | Mechanistic | DGIdb | |
| JNJ303 | ↓ inhibits | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| AMIFAMPRIDINE | ↓ inhibits | Mechanistic | DGIdb | |
| EPIRUBICIN | ? unclear | Mechanistic | DGIdb | |
| 3S,4R-293B | ↓ inhibits | Mechanistic | DGIdb | |
| REPAGLINIDE | ? unclear | Mechanistic | DGIdb | |
| VILDAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| R-L3 | ↑ activates | Mechanistic | DGIdb | |
| ML277 | ↑ activates | Mechanistic | DGIdb | |
| ICA-105665 | ? unclear | Mechanistic | DGIdb | |
| OXALIPLATIN | ? unclear | Mechanistic | DGIdb | |
| VOLINANSERIN | ↓ inhibits | Mechanistic | 1060.0 nM (Ki) | ChEMBL |
| CHEMBL1689654 | ↑ activates | Mechanistic | 49290.0 nM (EC50) | ChEMBL |
| CHEMBL1352968 | ↑ activates | Mechanistic | 1690.0 nM (EC50) | ChEMBL |
| CHEMBL2070830 | ↑ activates | Mechanistic | 1470.0 nM (EC50) | ChEMBL |
| CHEMBL2070832 | ↑ activates | Mechanistic | 1380.0 nM (EC50) | ChEMBL |
| CHEMBL2070952 | ↑ activates | Mechanistic | 890.0 nM (EC50) | ChEMBL |
Showing top 40 of 72 agents ranked by evidence tier.
RYR2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| RUTHENIUM RED | ↓ inhibits | Mechanistic | DGIdb | |
| MG2+ | ↓ inhibits | Mechanistic | DGIdb | |
| CAFFEINE | ↑ activates | Mechanistic | DGIdb | |
| VK-II-86 | ↓ inhibits | Mechanistic | DGIdb | |
| RYANODINE | ↓ inhibits | Mechanistic | DGIdb | |
| SURAMIN | ↑ activates | Mechanistic | DGIdb | |
| CA2+ | ↓ inhibits | Mechanistic | DGIdb | |
| ADENOSINE TRIPHOSPHATE | ↑ activates | Mechanistic | DGIdb | |
| CERIVASTATIN | ? unclear | Mechanistic | DGIdb | |
| PROCAINE | ↓ inhibits | Mechanistic | DGIdb | |
| CARVEDILOL | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL3941132 | ↑ activates | Mechanistic | 150.0 nM (EC50) | ChEMBL |
| CHEMBL3932239 | ↑ activates | Mechanistic | 211.0 nM (EC50) | ChEMBL |
| CHEMBL3902651 | ↑ activates | Mechanistic | 102.0 nM (EC50) | ChEMBL |
| CHEMBL3899882 | ↑ activates | Mechanistic | 208.0 nM (EC50) | ChEMBL |
| CHEMBL3961593 | ↑ activates | Mechanistic | 252.0 nM (EC50) | ChEMBL |
| CHEMBL3952083 | ↑ activates | Mechanistic | 55.0 nM (EC50) | ChEMBL |
| CHEMBL3909362 | ↑ activates | Mechanistic | 205.0 nM (EC50) | ChEMBL |
| CHEMBL3906571 | ↑ activates | Mechanistic | 181.0 nM (EC50) | ChEMBL |
| CHEMBL3933756 | ↑ activates | Mechanistic | 197.0 nM (EC50) | ChEMBL |
| CHEMBL3936508 | ↑ activates | Mechanistic | 174.0 nM (EC50) | ChEMBL |
| CHEMBL3895741 | ↑ activates | Mechanistic | 182.0 nM (EC50) | ChEMBL |
| CHEMBL3898439 | ↑ activates | Mechanistic | 265.0 nM (EC50) | ChEMBL |
| CHEMBL3949995 | ↑ activates | Mechanistic | 355.0 nM (EC50) | ChEMBL |
| CHEMBL3902432 | ↑ activates | Mechanistic | 268.0 nM (EC50) | ChEMBL |
| CHEMBL3982028 | ↑ activates | Mechanistic | 40.0 nM (EC50) | ChEMBL |
| CHEMBL3933375 | ↑ activates | Mechanistic | 40.0 nM (EC50) | ChEMBL |
| CHEMBL3928727 | ↑ activates | Mechanistic | 50.0 nM (EC50) | ChEMBL |
| ALADORIAN | ↑ activates | Mechanistic | 15.0 nM (EC50) | ChEMBL |
| CHEMBL3984280 | ↑ activates | Mechanistic | 44.0 nM (EC50) | ChEMBL |
| CHEMBL3932540 | ↑ activates | Mechanistic | 100.0 nM (EC50) | ChEMBL |
| CHEMBL3957737 | ↑ activates | Mechanistic | 80.0 nM (EC50) | ChEMBL |
| CHEMBL3984065 | ↑ activates | Mechanistic | 121.0 nM (EC50) | ChEMBL |
| CHEMBL3893618 | ↑ activates | Mechanistic | 80.0 nM (EC50) | ChEMBL |
| CHEMBL3918890 | ↑ activates | Mechanistic | 150.0 nM (EC50) | ChEMBL |
| CHEMBL3958409 | ↑ activates | Mechanistic | 20.0 nM (EC50) | ChEMBL |
| CHEMBL3953088 | ↑ activates | Mechanistic | 81.0 nM (EC50) | ChEMBL |
| CHEMBL3965149 | ↑ activates | Mechanistic | 40.0 nM (EC50) | ChEMBL |
| CHEMBL3961914 | ↑ activates | Mechanistic | 175.0 nM (EC50) | ChEMBL |
| CHEMBL3925184 | ↑ activates | Mechanistic | 143.0 nM (EC50) | ChEMBL |
Showing top 40 of 68 agents ranked by evidence tier.
SCN5A
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| COCAINE | ? unclear | Mechanistic | DGIdb | |
| PROCAINAMIDE | ? unclear | Mechanistic | DGIdb | |
| CHLOROPROCAINE | ↓ inhibits | Mechanistic | DGIdb | |
| DICHLOROBENZYL ALCOHOL | ↓ inhibits | Mechanistic | DGIdb | |
| PHENACEMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| INDECAINIDE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ETHOTOIN | ↓ inhibits | Mechanistic | DGIdb | |
| PROPOXYCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| RANOLAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| MORICIZINE | ? unclear | Mechanistic | DGIdb | |
| FOSPHENYTOIN | ↓ inhibits | Mechanistic | DGIdb | |
| QUINIDINE | ? unclear | Mechanistic | 6900.0 nM (IC50) | DGIdb |
| LIDOCAINE | ↓ inhibits | Mechanistic | DGIdb | |
| FLECAINIDE ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| LIDOCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PROCAINAMIDE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| QUINIDINE SULFATE | ↓ inhibits | Mechanistic | DGIdb | |
| HEXYLCAINE | ? unclear | Mechanistic | DGIdb | |
| LACOSAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| NKTR-171 | ↓ inhibits | Mechanistic | DGIdb | |
| ZONISAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DISOPYRAMIDE | ? unclear | Mechanistic | DGIdb | |
| PHENYTOIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| PRENYLAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| TOCAINIDE | ? unclear | Mechanistic | DGIdb | |
| AMIODARONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| QUINIDINE GLUCONATE | ↓ inhibits | Mechanistic | DGIdb | |
| PRIMIDONE | ↓ inhibits | Mechanistic | DGIdb | |
| BENZONATATE | ? unclear | Mechanistic | DGIdb | |
| ESLICARBAZEPINE ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| PROPAFENONE | ? unclear | Mechanistic | 3300.0 nM (IC50) | DGIdb |
| CENOBAMATE | ↓ inhibits | Mechanistic | DGIdb | |
| HEXYLCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| AZD7009 | ↓ inhibits | Mechanistic | DGIdb | |
| PRILOCAINE | ↓ inhibits | Mechanistic | DGIdb | |
| TOPIRAMATE | ↓ inhibits | Mechanistic | DGIdb | |
| LAMOTRIGINE | ↓ inhibits | Mechanistic | 62000.0 nM (IC50) | DGIdb |
| LOMERIZINE | ? unclear | Mechanistic | DGIdb | |
| CARBAMAZEPINE | ↓ inhibits | Mechanistic | DGIdb | |
| DRONEDARONE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 288 agents ranked by evidence tier.
TGFB1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| PIOGLITAZONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| SILYMARIN | ? unclear | Mechanistic | DGIdb | |
| RITUXIMAB | ? unclear | Mechanistic | DGIdb | |
| VERAPAMIL | ? unclear | Mechanistic | DGIdb | |
| PROTEASOME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| FRESOLIMUMAB | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| BINTRAFUSP ALFA | ~ modulates | Mechanistic | DGIdb | |
| NISEVOKITUG | ? unclear | Mechanistic | DGIdb | |
| LUSPATERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| TRETINOIN | ? unclear | Mechanistic | DGIdb | |
| HYDROCORTISONE BUTYRATE | ? unclear | Mechanistic | DGIdb | |
| VITAMIN E | ? unclear | Mechanistic | DGIdb | |
| IRINOTECAN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| INOSITOL | ? unclear | Mechanistic | DGIdb | |
| NICOTINE POLACRILEX | ? unclear | Mechanistic | DGIdb | |
| FENRETINIDE | ? unclear | Mechanistic | DGIdb | |
| MELATONIN | ? unclear | Mechanistic | DGIdb | |
| ISOTRETINOIN | ? unclear | Mechanistic | DGIdb | |
| VACTOSERTIB | ? unclear | Mechanistic | 12.9 nM (IC50) | DGIdb |
| TRIAMCINOLONE | ? unclear | Mechanistic | DGIdb | |
| TAMOXIFEN | ? unclear | Mechanistic | DGIdb | |
| ADRIAMYCIN | ? unclear | Mechanistic | DGIdb | |
| HEPARAN SULFATE | ? unclear | Mechanistic | DGIdb | |
| GOSSYPOL | ? unclear | Mechanistic | DGIdb | |
| TCDD | ? unclear | Mechanistic | DGIdb | |
| AMIFOSTINE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| RAMIPRIL | ? unclear | Mechanistic | DGIdb | |
| ANTIOXIDANT | ? unclear | Mechanistic | DGIdb | |
| SOTATERCEPT | ? unclear | Mechanistic | DGIdb | |
| ASPIRIN | ? unclear | Mechanistic | DGIdb | |
| GALUNISERTIB | ? unclear | Mechanistic | DGIdb | |
| KEYHOLE LIMPET HEMOCYANIN | ? unclear | Mechanistic | DGIdb | |
| PIRFENIDONE | ? unclear | Mechanistic | DGIdb | |
| H2O2 | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC ANDROGEN | ? unclear | Mechanistic | DGIdb | |
| SANDOSTATIN | ? unclear | Mechanistic | DGIdb | |
| BROXURIDINE | ? unclear | Mechanistic | DGIdb | |
| DISITERTIDE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 62 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Atrial Fibrillation: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
Pulsed Field Ablation (PFA) has created a 'paradigm shift' within cardiac electrophysiology and the initial experience demonstrates that PFA is safe, rapid and effective compared to both radiofrequency ablation and cryoablation in atrial fibrillation (AF). Presently, AF ablation procedures in the UK...
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
PFA is an emerging non-thermal ablation technology with favorable procedural safety; however, recent studies have raised concerns about peri-procedural hemolysis and subsequent AKI after PFA. This study is a single-center, open-label, randomized controlled trial designed to evaluate whether standard...
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how ...
The goal of this clinical trial is to learn whether the antiarrhythmic drug flecainide can be used as safely as standard rhythm-control drugs in people with atrial fibrillation (AF) and stable coronary artery disease (CAD). The study includes adults aged 18 years and older who have AF and known but ...
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillati...
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when...
This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase wi...
The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called ele...
The prevention of perioperative atrial fibrillation (AF) and myocardial injury after non-cardiac surgery (MINS) has the potential to reduce mortality, stroke, and hospital stays in patients undergoing major thoracic surgery. Data from cardiac surgery patients suggest that prevention of perioperative...
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can s...
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in partic...
ACE-AF is a multicenter randomized study in people aged 78 years and older with symptomatic atrial fibrillation (AF). AF is a common heart rhythm disorder in older adults and can cause reduced quality of life and lead to serious complications such as stroke and heart failure. The study compares two ...
This is a multi-national, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil NS in patients with atrial fibrillation (AF). This study includes Screening Visit, Randomization Visit, a Treatment Period with scheduled Follow-up Visits (Monthly Follow-u...
Agents Found By Disease-Level Search
Searched directly from “Atrial Fibrillation” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
40 agents shown (approved or with trial evidence) — 37 not found by the gene-target search above.
DabigatranNOT in gene-target list
RivaroxabanNOT in gene-target list
Oral anticoagulantNOT in gene-target list
BWLT+CRNOT in gene-target list
CR-OnlyNOT in gene-target list
bucindolol hydrochloride
metoprolol succinate
Apixaban Oral TabletNOT in gene-target list
Edoxaban TabletsNOT in gene-target list
12-Lead ECGNOT in gene-target list
ECG-I Mapping of Atrial FibrillationNOT in gene-target list
EdoxabanNOT in gene-target list
Adaptive Servo-VentilationNOT in gene-target list
continue warfarin through the procedureNOT in gene-target list
Hold warfarinNOT in gene-target list
Warfarin held with heparin transition.NOT in gene-target list
PVI aloneNOT in gene-target list
IvabradineNOT in gene-target list
EthanolNOT in gene-target list
Hybrid procedureNOT in gene-target list
left atrial appendage occlusionNOT in gene-target list
Aggressive Risk Factor ControlNOT in gene-target list
Ambulatory ECGNOT in gene-target list
DiagnosticNOT in gene-target list
Standard escalating shocksNOT in gene-target list
High energy shock protocolNOT in gene-target list
Antiarrhythmic Drug TherapyNOT in gene-target list
Study WatchNOT in gene-target list
optimizer smartNOT in gene-target list
Termination of AFNOT in gene-target list
WarfarinNOT in gene-target list
Antiarrhythmic drugNOT in gene-target list
ICE Image guidanceNOT in gene-target list
14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)NOT in gene-target list
Bisoprolol
DigoxinNOT in gene-target list
Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wallNOT in gene-target list
Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wallNOT in gene-target list
Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wallNOT in gene-target list
Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wallNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.